Quotient Limited Announces receipt of Note Holders Consents to Indenture Amendments That Extend Maturity, Defer Principal Payments on 12% Senior Secured Notes
Quotient Limited (NASDAQ:QTNT) has secured unanimous consent from holders of its 12% Senior Secured Notes to amend the notes' terms. The amendments include an 18-month extension of the maturity to October 2025 and a revised amortization schedule, deferring approximately $60 million in principal payments until April 2023. The company will issue 932,772 ordinary shares and warrants to purchase 1,844,020 ordinary shares at $4 each as part of this agreement. This allows Quotient to enhance liquidity and pursue the commercial launch of its MosaiQ technology.
- Cash obligations reduced by approximately $60 million.
- Extended liquidity runway through October 2025, allowing for further investment in MosaiQ.
- Enhances the company's ability to execute MosaiQ's commercial launch.
- None.
- Notes holders unanimously consent to amendments
- Company’s near-term cash obligations reduced by approximately
$60 million - Transaction extends liquidity runway through commercial launch and provides resources for further MosaiQ investment
JERSEY, Channel Islands, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced it has received unanimous consents from the holders of its
The Indenture Amendments include an 18-month extension of the final maturity of the Notes to October 2025 and a revision of the Notes' principal amortization schedule (which previously required semi-annual payments of principal beginning April 2021) to commence April 2023. The revised amortization schedule will defer approximately
In consideration of the Note holders' consents to the amendments, the Company agreed to issue them an aggregate of 932,772 of the Company's ordinary shares and 5-year warrants to purchase an aggregate of 1,844,020 of the Company's ordinary shares for
“I am very pleased to have reached an agreement with our existing Note holders. This agreement improves our liquidity and provides us with additional freedom to execute on the commercial launch of MosaiQ and further advance the MosaiQ pipeline.” said Manuel O. Méndez, Chief Executive Officer of Quotient. “The continued support from our existing stakeholders since my arrival has been tremendous and demonstrates their confidence in the MosaiQ solution and our Company as a whole.”
About Quotient Limited
Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. In response to the global effort to combat COVID-19, Quotient developed the MosaiQ COVID-19 Antibody Microarray which is CE marked and has received the U.S. FDA Emergency Use Authorization. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include statements regarding our expectations of continued growth, the development, regulatory approval, commercialization and impact of MosaiQ and other new products (including the potential for using the Company’s MosaiQ technology to infectious disease diagnostics), current estimates of first quarter and full year fiscal 2022 operating results and expectations regarding our future funding sources. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include delays or denials of regulatory approvals or clearances for products or applications; market acceptance of our products; the impact of competition; the impact of facility expansions and expanded product development, clinical, sales and marketing activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or field trial studies; adverse results in connection with any ongoing or future legal proceedings; continued or worsening adverse conditions in the general domestic and global economic markets, including as a result of the global COVID-19 pandemic; as well as the other risks set forth in the Company's filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Quotient disclaims any obligation to update these forward-looking statements.
The Quotient logo, Quotient MosaiQ and MosaiQ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
Contact: IR@quotientbd.com; +41 22 545 52 26
FAQ
What recent financial amendments has Quotient Limited made regarding its Senior Secured Notes?
How will the recent amendments affect Quotient Limited's liquidity?
What is the significance of the shareholders' consent for Quotient Limited?
How many shares and warrants will Quotient Limited issue as part of the financing agreement?
What technology is Quotient Limited focusing on for its commercial launch?
